| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5554180 | Clinical Therapeutics | 2016 | 12 Pages |
Abstract
Adherence to non-vitamin K antagonist oral anticoagulants among NVAF patients is less than ideal, and gaps in treatment are common. Those on once-a-day rivaroxaban had significantly higher adherence and fewer gaps in treatment compared with twice-a-day apixaban. Future studies are needed to explore whether these treatment differences affect comparative patient outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Colleen A. MD, Eric D. MD, MPH, FAHA, FACC, François MA, Guillaume MA, Winnie W. MS, MBA, Concetta MPH, Jeffrey PhD, Patrick MA,